Liaoran Wang

Liaoran Wang

Auto-generated profile, based on publicly available information

Liaoran Wang

Second Affiliated Hospital of Hainan Medical University Haikou China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2025 in Liver Transplantation
Verified
Journal Article
Closed access
LWLiaoran Wang
Liaoran Wang
HHHidetaka Hara
Hidetaka Hara
DCDavid Cooper
David Cooper
YWYi Wang
Yi Wang
QWQiang Wei
Qiang Wei
XXXiao Xu
Xiao Xu
Advances in both gene editing of organ-source pigs and novel immunosuppressive therapies have substantially propelled the field of heart and kidney xenotransplantation forward, and have helped in overcoming challenges associated with porcine liver transplantation. In this review, the recent experience with porcine liver xenotransplantation in China for both decedents and living patients is discussed. We suggest that porcine liver xenografts play a much greater role in the management of patients with hepatic failure awaiting or following liver allotransplantation. Additionally, we propose that brain-dead human subjects (decedents) be used to validate the efficacy of porcine livers in supporting split or marginal human liver grafts. These developments are expected to lay the groundwork for clinical trials aimed at improving the outcomes of patients with end-stage liver disease, potentially expanding the pool of transplantable organs and providing new therapeutic options for these patients. Export

28 September 2023 in European Heart Journal - Case Reports
Verified
Journal Article
Open access
PDF file
LWLiaoran Wang
Liaoran Wang
YZYu Zhang
Yu Zhang
HYHang Yu
Hang Yu
JSJiangping Song
Jiangping Song
YWYi Wang
Yi Wang
Background: Multi-organ transplantation has emerged as a viable treatment strategy for patients afflicted with multiple organ failure or significant organ dysfunctions. Despite the promising therapeutic outcomes, this approach also amplifies the risk of organ rejection, infection, or neoplastic growth. We present a unique case of a patient who sequentially underwent liver, kidney, and heart transplantation, all sourced from different donors. This case brings forth intriguing possibilities about the interplay between cardiovascular diseases and complications arising post-transplantation, thereby enriching our understanding of comprehensive transplant immunomodulation and cardiovascular disease prevention. Case summary: A 59-year-old male with chronic alcohol misuse developed liver cirrhosis in 2012 and subsequent kidney failure in 2018 due to alcoholic liver disease, type II diabetes, hyperlipidaemia, and severe hypertension. Subsequently, an incident of extensive transmural myocardial infarction (Killip III) warranted a heart transplant in 2022. Post-transplant, the patient was maintained on a standard immunosuppression regimen with regular post-operative follow-ups. No signs of rejection were noted 1-year post-final transplantation under standard immunosuppression. Discussion: The presented case exemplifies the potential and feasibility of sequential multi-organ transplantation. The multifaceted interplay between the transplanted organs and the immunosuppressive pharmaceuticals likely exert distinct influences on transplantation immune regulation, possibly diverging from the dynamics observed in single-organ transplantation. A comprehensive exploration of the mechanisms governing immune responses in the context of multi-organ transplantation could yield valuable insights for mitigating graft dysfunction. Furthermore, the rapid progression of atherosclerosis observed after liver and kidney transplantation necessitates further scrutiny to elucidate potential correlations with the post-transplantation state.

1 May 2026 in Xenotransplantation
Verified
Journal Article
Open access
CGCorbin E. Goerlich
Corbin E. Goerlich
ESEvelyn J. Salvaris
Evelyn J. Salvaris
KFKonrad Fischer
Konrad Fischer
ACAntonio Citro
Antonio Citro
AGAlessia Giarraputo
Alessia Giarraputo
RMRaphael Meier
Raphael Meier
Xenotransplantation has been iteratively improved over the last decade in pre‐clinical models, with first‐in‐human clinical trials underway. The 2025 IXA Congress in Geneva was held in parallel with meetings involving World Health Organization leaders to support the development of new guidance on xenotransplantation in this rapidly evolving field. Key scientific themes of the meeting included the introduction of multiple‐gene edited pigs for xenotransplantation research and clinical trials, better characterization of innate and adaptive immune responses and xenograft preservation that optimizes ramifications of ischemia‐reperfusion injury during implantation. This comes at a time when gene‐edited pig organs are being used for human xenotransplantation, a development that demands safety, reproducibility, durability, and a clear mechanistic understanding of rejection and tolerance.

17 November 2026 in Xenotransplantation
Verified
Journal Article
Open access
DEDaniel Eisenson
Daniel Eisenson
EMEmilien Seizilles de Mazancourt
Emilien Seizilles de Mazancourt
JLJoseph M Ladowski
Joseph M Ladowski
ESEvelyn J. Salvaris
Evelyn J. Salvaris
KFKonrad Fischer
Konrad Fischer
RMRaphael Meier
Raphael Meier
The 2025 International Xenotransplantation Association (IXA) Congress in Geneva, convened in parallel with World Health Organization meetings on xenotransplantation guidance, marked a transition in clinical xenotransplantation from demonstrating that pig organs can function in humans to defining how graft injury is detected, interpreted, and managed in real time. We synthesize the major clinical themes that emerged from the meeting across kidney, heart, liver, and lung xenotransplantation. In kidney xenotransplantation, the NYU and Massachusetts General Hospital living‐recipient experiences now delineate two complementary injury patterns—antibody‐ and complement‐driven with a membranoproliferative, IgA‐positive, innate‐rich phenotype, and T cell–mediated with persistent innate immune activation—both converging on macrophage and NK‐cell biology that conventional immunosuppression does not address. The first registration‐supporting Phase 1/2/3 trial of a 10‐gene‐edited xenokidney (EXPAND) has begun, framed by IXA position‐paper recommendations and supported by recent FDA approvals. In cardiac xenotransplantation, real‐time complement‐function monitoring, global longitudinal strain, and donor‐derived cell‐free DNA emerge as an actionable surveillance toolkit, while other allotransplant biomarkers translate poorly. In liver xenotransplantation, extracorporeal cross‐circulation and the first preliminary data describing auxiliary pig‐to‐human liver transplant (171‐day survival) position porcine livers as bridge‐support platforms rather than definitive replacements. Lung xenotransplantation remains confined to ex vivo perfusion and short‐term preclinical models. Cross‐cutting priorities include donor‐pig design and individual graft phenotyping that accounts for transgene expression heterogeneity, prospectively validated multimodal monitoring, management of nephrotic‐range proteinuria and associated urinary loss of biologic immunosuppressants, and dedicated registry, ethical, and patient‐engagement infrastructure to support trustworthy clinical expansion.